CN115737902A - Medical recombinant III-type humanized collagen gel - Google Patents
Medical recombinant III-type humanized collagen gel Download PDFInfo
- Publication number
- CN115737902A CN115737902A CN202211394796.4A CN202211394796A CN115737902A CN 115737902 A CN115737902 A CN 115737902A CN 202211394796 A CN202211394796 A CN 202211394796A CN 115737902 A CN115737902 A CN 115737902A
- Authority
- CN
- China
- Prior art keywords
- parts
- prepared
- weight
- following components
- collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000512 collagen gel Substances 0.000 title claims abstract description 25
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 42
- 102000008186 Collagen Human genes 0.000 claims abstract description 30
- 108010035532 Collagen Proteins 0.000 claims abstract description 30
- 229920001436 collagen Polymers 0.000 claims abstract description 30
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 14
- 239000002253 acid Substances 0.000 claims abstract description 14
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 14
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 14
- 239000000230 xanthan gum Substances 0.000 claims abstract description 14
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 14
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 14
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 14
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims abstract description 13
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims abstract description 13
- 239000008213 purified water Substances 0.000 claims abstract description 13
- 229940087068 glyceryl caprylate Drugs 0.000 claims abstract description 12
- 229960005150 glycerol Drugs 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 8
- 229960005188 collagen Drugs 0.000 claims abstract description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 6
- -1 caprylyl hydroxamic Chemical compound 0.000 claims description 5
- 239000004698 Polyethylene Substances 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 4
- 229910001385 heavy metal Inorganic materials 0.000 claims description 4
- 238000007654 immersion Methods 0.000 claims description 4
- 230000009972 noncorrosive effect Effects 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract description 15
- 230000004054 inflammatory process Effects 0.000 abstract description 14
- 239000000203 mixture Substances 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 230000029663 wound healing Effects 0.000 abstract description 8
- 230000036573 scar formation Effects 0.000 abstract description 7
- 230000008439 repair process Effects 0.000 abstract description 6
- 208000012641 Pigmentation disease Diseases 0.000 abstract description 5
- 230000019612 pigmentation Effects 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 208000027418 Wounds and injury Diseases 0.000 description 14
- 206010052428 Wound Diseases 0.000 description 13
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 206010048218 Xeroderma Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000013532 laser treatment Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the technical field of biological medicines, and particularly relates to a medical recombinant III-type humanized collagen gel which is prepared from recombinant human collagen, sodium hyaluronate, xanthan gum, glycerol, caprylyl hydroximic acid, glyceryl caprylate, hexanediol and purified water according to a specific matching proportion of a formula: the recombinant human collagen is prepared from the following components in parts by weight: 3-5 parts; the sodium hyaluronate is prepared from the following components in parts by weight: 1-3 parts; the xanthan gum is prepared from the following components in parts by weight: 3-5 parts; the glycerol is prepared from the following components in parts by weight: 3-5 parts; the octanoyl hydroximic acid is prepared from the following components in parts by weight: 1-2 parts; the glyceryl caprylate is prepared from the following components in parts by weight: 4-6 parts of the traditional Chinese medicine composition, has reasonable structure, promotes wound healing and skin repair, shortens the course of disease, and relieves the risk of pigmentation and scar formation after inflammation in the using process.
Description
Technical Field
The invention relates to the technical field of biological medicines, in particular to medical recombinant III-type humanized collagen gel.
Background
The gynecological vaginitis, the cervicitis and the cervical erosion are common and frequent diseases in gynecological diseases, the female suffers from vaginal pruritus, vaginal secretion is increased, peculiar smell is generated, and the cervical erosion is recurrent, so that the physical and psychological health of the female is seriously affected. The gynecological inflammation is mainly caused by inflammatory reaction caused by destroying the ecological environment in the vagina, pH imbalance or local damage of the cervix, so that effective anti-inflammation, restoration of internal environment balance and cervical injury and restoration of the pH value in vivo is an effective means for thoroughly eradicating the gynecological inflammation. At present, the products for treating gynecological inflammation in the market are more, and are mostly spectral antibacterial antibiotics and nano-silver antibacterial preparations, the antibiotics can generate drug resistance after being used for a long time, and beneficial bacteria are killed while harmful bacteria are killed. The nano-silver antibacterial preparation has stronger antibacterial and bactericidal effects, but does not have a repairing function, treats the symptoms but not the root causes, so that inflammation is easy to relapse.
The wound dressing is used as a temporary covering of a wound, can temporarily replace damaged skin to play a role in protection in the process of wound healing, prevents wound infection and inflammation, and provides a favorable environment for the rapid healing of the wound. Because a series of problems such as wound adhesion, poor moisture retention, susceptibility to infection, no healing promotion effect and the like exposed in the using process of traditional dressings such as gauze, bandage and the like, with the development of materials science and industry science, various novel dressings gradually replace the traditional dressings and play an important role in the field of wound repair. The novel medical dressing is a wound dressing developed based on a moist healing concept, can effectively maintain the wetness of a wound surface, accelerate the repair of the wound surface and reduce the infection of the wound, and is also more convenient to use. The hydrogel is one of the products, and is generally a fluid or semi-fluid with extremely high water content formed by dispersing water-soluble polymers in water, and the main functions of the products are to provide a moist environment for wounds, promote wound healing and reduce scar formation. The collagen is used as one of main components for constructing the extracellular matrix skeleton, has low immunogenicity, good biocompatibility and biodegradability, promotes the biological activity of cell adhesion proliferation, and can accelerate the speed of wound repair and healing. The polyvinylpyrrolidone which is a water-soluble high polymer material with good biocompatibility and widely used as a pharmaceutic adjuvant can reduce the generation of various proinflammatory factors such as interleukin-1 beta (IL-1 beta), tumor necrosis factor (TNF-alpha), transforming growth factor (TGF-beta 1) and the like when being mixed with collagen for use, and obviously reduce inflammatory reaction; and can remove collagen excessively deposited on the wound, promote tissue reconstruction and reduce scar formation.
Based on the above, we propose a medical recombinant type III humanized collagen gel.
Disclosure of Invention
This section is for the purpose of summarizing some aspects of embodiments of the invention and to briefly introduce some preferred embodiments. In this section, as well as in the abstract and the title of the invention of this application, simplifications or omissions may be made to avoid obscuring the purpose of the section, the abstract and the title, and such simplifications or omissions are not intended to limit the scope of the invention.
The present invention has been made keeping in mind the above problems occurring in the prior art.
Therefore, the invention aims to provide a medical recombinant III-type humanized collagen gel which can promote wound healing and skin repair, shorten the course of disease and reduce the risk of pigmentation and scar formation after inflammation in the using process.
In order to solve the above technical problems, according to one aspect of the present invention, the present invention provides the following technical solutions:
the medical recombinant III-type humanized collagen gel comprises recombinant human collagen, sodium hyaluronate, xanthan gum, glycerol, caprylyl hydroximic acid, glyceryl caprylate, hexanediol and purified water, and is prepared according to the specific matching proportion of the formula:
wherein,
the recombinant human collagen is prepared from the following components in parts by weight: 3-5 parts;
the sodium hyaluronate is prepared from the following components in parts by weight: 1-3 parts;
the xanthan gum is prepared from the following components in parts by weight: 3-5 parts;
the glycerol is prepared from the following components in parts by weight: 3-5 parts;
the octanoyl hydroximic acid is prepared from the following components in parts by weight: 1-2 parts;
the glyceryl caprylate is prepared from the following components in parts by weight: 4-6 parts;
the hexanediol is prepared from the following components in parts by weight: 1-2 parts;
the purified water is prepared from the following components in parts by weight: 50-100 parts.
As a preferable embodiment of the medical recombinant type III humanized collagen gel of the present invention, wherein: the recombinant human collagen is prepared by concentrating a collagen solution with the initial concentration of 3-4 mg/mL by using polyethylene glycol (PEG).
As a preferable embodiment of the medical recombinant type III humanized collagen gel of the present invention, wherein: the content of the recombinant human collagen is not less than 0.03 percent (mass fraction); the pH value is 5.0-7.5; the heavy metal content should not exceed 10. Mu.g/g.
As a preferable embodiment of the medical recombinant type III humanized collagen gel of the present invention, wherein: the preparation process comprises the following steps:
firstly, concentrating collagen solution with initial concentration of 3-4 mg/mL to 1-3 wt% by using ethylene glycol; then sequentially adding sodium hyaluronate, xanthan gum, glycerol, caprylyl hydroximic acid, glycerol caprylate, hexanediol and purified water, fully dissolving, uniformly stirring at room temperature, stirring to form a homogenate shape, and performing centrifugal deaeration; and finally, checking and subpackaging into polyethylene bottles to obtain the medical recombinant III-type humanized collagen gel.
As a preferable embodiment of the medical recombinant type III humanized collagen gel of the present invention, wherein: the using method comprises the following steps: for external use, cleaning affected part skin, opening external package, squeezing out gel at a ratio of 0.1g/cm 2 The wound surface is applied uniformly 3 times a day.
As a preferable embodiment of the medical recombinant type III humanized collagen gel of the present invention, wherein: the transport and storage conditions were as follows: storing at normal temperature in a dry, ventilated and non-corrosive gas environment; during transportation, heavy pressure, direct sunlight and rain and snow immersion should be prevented.
Compared with the prior art, the invention has the beneficial effects that:
the Chinese medicinal composition is suitable for inhibiting and relieving skin inflammatory reaction caused by various reasons such as dermatitis, atopic dermatitis, laser-dependent dermatitis, xeroderma, sensitive skin, acne, after laser treatment and the like, promoting wound healing and skin repair, shortening the course of disease, reducing the risk of pigmentation and scar formation after inflammation, and has certain auxiliary treatment effect on the diseases.
Detailed Description
The present invention will be described in detail with reference to the following embodiments in order to make the aforementioned objects, features and advantages of the invention more comprehensible.
In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention, but the present invention may be practiced in other ways than those specifically described herein, and it will be apparent to those of ordinary skill in the art that the present invention may be practiced without departing from the spirit and scope of the present invention, and therefore the present invention is not limited to the specific embodiments disclosed below.
In order to make the objects, technical solutions and advantages of the present invention more apparent, embodiments of the present invention will be described in further detail below.
The invention provides the following technical scheme: a medical recombinant type III humanized collagen gel can promote wound healing and skin repair, shorten course of disease, and reduce risk of pigmentation and scar formation after inflammation;
example 1
The medical recombinant III-type humanized collagen gel comprises recombinant human collagen, sodium hyaluronate, xanthan gum, glycerol, caprylyl hydroximic acid, glyceryl caprylate, hexanediol and purified water, and is prepared according to the specific matching proportion of the formula:
wherein,
the recombinant human collagen is prepared from the following components in parts by weight: 3 parts of a mixture;
the sodium hyaluronate is prepared from the following components in parts by weight: 1 part;
the xanthan gum is prepared from the following components in parts by weight: 3 parts of a mixture;
the glycerol is prepared from the following components in parts by weight: 3 parts of a mixture;
the octanoyl hydroximic acid is prepared from the following components in parts by weight: 1 part;
the glyceryl caprylate is prepared from the following components in parts by weight: 4 parts of a mixture;
the hexanediol is prepared from the following components in parts by weight: 1 part;
the purified water is prepared from the following components in parts by weight: 50 parts of the components.
Wherein: the recombinant human collagen is prepared by concentrating a collagen solution with the initial concentration of 3-4 mg/mL by using polyethylene glycol (PEG).
Wherein: the content of the recombinant human collagen is not less than 0.03 percent (mass fraction); the pH value should be 5.0-7.5; the heavy metal content should not exceed 10. Mu.g/g.
Wherein: the preparation process comprises the following steps:
firstly, concentrating collagen solution with initial concentration of 3-4 mg/mL to 1-3 wt% by using ethylene glycol; then sequentially adding sodium hyaluronate, xanthan gum, glycerol, caprylyl hydroximic acid, glyceryl caprylate, hexanediol and purified water, fully dissolving, uniformly stirring at room temperature, stirring to form a homogenate, and centrifuging to defoam; and finally, checking and subpackaging into polyethylene bottles to obtain the medical recombinant III-type humanized collagen gel.
Wherein: the using method comprises the following steps: for external use, cleaning affected part skin, opening external package, squeezing out gel at a ratio of 0.1g/cm 2 The wound surface is applied uniformly 3 times daily.
Wherein: the transport and storage conditions were as follows: storing at normal temperature in a dry, ventilated and non-corrosive gas environment; during transportation, heavy pressure, direct sunlight and rain and snow immersion should be prevented.
Example 2
The medical recombinant III-type humanized collagen gel comprises recombinant human collagen, sodium hyaluronate, xanthan gum, glycerol, caprylyl hydroximic acid, glyceryl caprylate, hexanediol and purified water, and is prepared according to the specific matching proportion of the formula:
wherein,
the recombinant human collagen is prepared from the following components in parts by weight: 5 parts of a mixture;
the sodium hyaluronate is prepared from the following components in parts by weight: 3 parts of a mixture;
the xanthan gum is prepared from the following components in parts by weight: 5 parts of a mixture;
the glycerol is prepared from the following components in parts by weight: 5 parts of a mixture;
the octanoyl hydroximic acid is prepared from the following components in parts by weight: 2 parts of (1);
the glyceryl caprylate is prepared from the following components in parts by weight: 6 parts;
the hexanediol is prepared from the following components in parts by weight: 2 parts of (1);
the purified water is prepared from the following components in parts by weight: 100 parts.
Wherein: the recombinant human collagen is prepared by concentrating collagen solution with initial concentration of 3-4 mg/mL by using polyethylene glycol (PEG).
Wherein: the content of the recombinant human collagen is not less than 0.03 percent (mass fraction); the pH value is 5.0-7.5; the heavy metal content should not exceed 10. Mu.g/g.
Wherein: the specific preparation process comprises the following steps:
firstly, concentrating collagen solution with initial concentration of 3-4 mg/mL to 1-3 wt% by using ethylene glycol; then sequentially adding sodium hyaluronate, xanthan gum, glycerol, caprylyl hydroximic acid, glycerol caprylate, hexanediol and purified water, fully dissolving, uniformly stirring at room temperature, stirring to form a homogenate shape, and performing centrifugal deaeration; and finally, checking and subpackaging into polyethylene bottles to obtain the medical recombinant III-type humanized collagen gel.
Wherein: the using method comprises the following steps: for external use, cleaning affected part skin, opening external package, squeezing out gel at a ratio of 0.1g/cm 2 The wound surface is applied uniformly 3 times daily.
Wherein: transportation and storage conditions were as follows: storing at normal temperature in a dry, ventilated and non-corrosive gas environment; during transportation, heavy pressure, direct sunlight and rain and snow immersion should be prevented
The working principle is as follows: the invention is suitable for inhibiting and relieving skin inflammatory reaction caused by various reasons such as dermatitis, atopic dermatitis, laser-dependent dermatitis, xeroderma, sensitive skin, acne, after laser treatment and the like, promoting wound healing and skin repair, shortening the course of disease, reducing the risk of pigmentation and scar formation after inflammation and having certain auxiliary treatment effect on the diseases.
While the invention has been described above with reference to an embodiment, various modifications may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. In particular, the various features of the disclosed embodiments of the invention may be used in any combination, provided that no structural conflict exists, and the combinations are not exhaustively described in this specification merely for the sake of brevity and resource conservation. Therefore, it is intended that the invention not be limited to the particular embodiments disclosed, but that the invention will include all embodiments falling within the scope of the appended claims.
Claims (6)
1. A medical recombinant type III humanized collagen gel is characterized in that: the collagen peptide is prepared from recombinant human collagen, sodium hyaluronate, xanthan gum, glycerol, caprylyl hydroxamic acid, glyceryl caprylate, hexanediol and purified water according to a specific formula matching proportion:
wherein,
the recombinant human collagen is prepared from the following components in parts by weight: 3-5 parts;
the sodium hyaluronate is prepared from the following components in parts by weight: 1-3 parts;
the xanthan gum is prepared from the following components in parts by weight: 3-5 parts;
the glycerol is prepared from the following components in parts by weight: 3-5 parts;
the octanoyl hydroximic acid is prepared from the following components in parts by weight: 1-2 parts;
the glyceryl caprylate is prepared from the following components in parts by weight: 4-6 parts;
the hexanediol is prepared from the following components in parts by weight: 1-2 parts;
the purified water is prepared from the following components in parts by weight: 50-100 parts.
2. The medical recombinant type III humanized collagen gel according to claim 1, wherein: the recombinant human collagen is prepared by concentrating collagen solution with initial concentration of 3-4 mg/mL by using polyethylene glycol (PEG).
3. The medical recombinant type III humanized collagen gel according to claim 1, wherein: the content of the recombinant human collagen is not less than 0.03 percent (mass fraction); the pH value should be 5.0-7.5; the heavy metal content should not exceed 10. Mu.g/g.
4. The medical recombinant type III humanized collagen gel according to claim 1, wherein: the specific preparation process comprises the following steps:
firstly, concentrating collagen solution with initial concentration of 3-4 mg/mL to 1-3 wt% by using ethylene glycol; then sequentially adding sodium hyaluronate, xanthan gum, glycerol, caprylyl hydroximic acid, glyceryl caprylate, hexanediol and purified water, fully dissolving, uniformly stirring at room temperature, stirring to form a homogenate, and centrifuging to defoam; and finally, checking and subpackaging into polyethylene bottles to obtain the medical recombinant III-type humanized collagen gel.
5. The medical recombinant type III humanized collagen gel according to claim 1, wherein: the using method comprises the following steps: for external use, cleaning affected part skin, opening external package, squeezing out gel at a ratio of 0.1g/cm 2 The wound surface is applied uniformly 3 times a day.
6. The medical recombinant type III humanized collagen gel according to claim 1, wherein: transportation and storage conditions were as follows: storing at normal temperature in a dry, ventilated and non-corrosive gas environment; during transportation, heavy pressure, direct sunlight and rain and snow immersion should be prevented.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211394796.4A CN115737902A (en) | 2022-11-07 | 2022-11-07 | Medical recombinant III-type humanized collagen gel |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211394796.4A CN115737902A (en) | 2022-11-07 | 2022-11-07 | Medical recombinant III-type humanized collagen gel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115737902A true CN115737902A (en) | 2023-03-07 |
Family
ID=85368609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211394796.4A Pending CN115737902A (en) | 2022-11-07 | 2022-11-07 | Medical recombinant III-type humanized collagen gel |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115737902A (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5196185A (en) * | 1989-09-11 | 1993-03-23 | Micro-Collagen Pharmaceutics, Ltd. | Collagen-based wound dressing and method for applying same |
| US20070154530A1 (en) * | 2005-09-12 | 2007-07-05 | Cullen Breda M | Wound dressings comprising oxidized cellulose and human recombinant collagen |
| US20140112973A1 (en) * | 2011-04-05 | 2014-04-24 | Albert-Ludwigs-Universitaet Freiburg | Biocompatible and biodegradable gradient layer system for regenerative medicine and for tissue support |
| CN106902381A (en) * | 2017-03-23 | 2017-06-30 | 陕西慧康生物科技有限责任公司 | Recombination human source collagen stoste, dressing and their preparation method |
| CN109988243A (en) * | 2019-01-29 | 2019-07-09 | 江苏悦智生物医药有限公司 | III collagen type α of recombination human source, 1 chain and its application |
| CN111150881A (en) * | 2020-01-16 | 2020-05-15 | 南京艾澜德生物科技有限公司 | Medical recombinant collagen spray and preparation method thereof |
| CN111867644A (en) * | 2018-03-22 | 2020-10-30 | 伦敦玛丽女王大学 | Implantable cell dressings for disease treatment |
| CN115089755A (en) * | 2022-07-28 | 2022-09-23 | 浙江美尚洁生物科技有限公司 | Medical dressing composition of recombined fibronectin-humanized collagen with repairing effect and preparation method thereof |
| WO2022232566A2 (en) * | 2021-04-30 | 2022-11-03 | Modern Meadow, Inc. | Collagen compositions and methods of use thereof |
-
2022
- 2022-11-07 CN CN202211394796.4A patent/CN115737902A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5196185A (en) * | 1989-09-11 | 1993-03-23 | Micro-Collagen Pharmaceutics, Ltd. | Collagen-based wound dressing and method for applying same |
| US20070154530A1 (en) * | 2005-09-12 | 2007-07-05 | Cullen Breda M | Wound dressings comprising oxidized cellulose and human recombinant collagen |
| US20140112973A1 (en) * | 2011-04-05 | 2014-04-24 | Albert-Ludwigs-Universitaet Freiburg | Biocompatible and biodegradable gradient layer system for regenerative medicine and for tissue support |
| CN106902381A (en) * | 2017-03-23 | 2017-06-30 | 陕西慧康生物科技有限责任公司 | Recombination human source collagen stoste, dressing and their preparation method |
| CN111867644A (en) * | 2018-03-22 | 2020-10-30 | 伦敦玛丽女王大学 | Implantable cell dressings for disease treatment |
| CN109988243A (en) * | 2019-01-29 | 2019-07-09 | 江苏悦智生物医药有限公司 | III collagen type α of recombination human source, 1 chain and its application |
| CN111150881A (en) * | 2020-01-16 | 2020-05-15 | 南京艾澜德生物科技有限公司 | Medical recombinant collagen spray and preparation method thereof |
| WO2022232566A2 (en) * | 2021-04-30 | 2022-11-03 | Modern Meadow, Inc. | Collagen compositions and methods of use thereof |
| CN115089755A (en) * | 2022-07-28 | 2022-09-23 | 浙江美尚洁生物科技有限公司 | Medical dressing composition of recombined fibronectin-humanized collagen with repairing effect and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104587518B (en) | Hyaluronic acid dressing and preparation method thereof | |
| CN111632075B (en) | Exosome preparation for promoting skin wound healing and preparation method thereof | |
| CN103159967B (en) | Preparation method of collagen-based sponge wound dressing with self-anti-inflammatory function | |
| CN114984301A (en) | Antibacterial dressing for promoting wound surface to heal without scars and preparation method thereof | |
| CN101879324A (en) | Preparation method of chitosan composite medical dressing | |
| CN116688212B (en) | III type recombinant collagen dressing with repairing and anti-aging effects and preparation method and application thereof | |
| CN101244286A (en) | A kind of hydrogel dressing and preparation method thereof | |
| CN107469139A (en) | A kind of preparation method of high intensity wound dressing with antibacterial and anti-inflammatory effects | |
| CN104306324A (en) | Medical collagen gel and preparation method thereof | |
| CN106728744A (en) | A kind of composition and its preparation of the promotion anti-scar of wound healing | |
| CN109224124B (en) | Liquid dressing for stopping bleeding and promoting healing | |
| CN108210888A (en) | A kind of periodontitis gel containing hyaluronic acid and preparation method thereof | |
| CN111150838A (en) | Collagen hydrogel for promoting wound healing and preparation method thereof | |
| CN115737902A (en) | Medical recombinant III-type humanized collagen gel | |
| CN109731040A (en) | A kind of wound remediation composition, preparation method and applications | |
| CN112121146B (en) | A topical gel for treating skin wound, and its preparation method | |
| CN109674743B (en) | Wound care gel and preparation method thereof | |
| RU2329822C1 (en) | Antiseptic, anti-inflammatory, analgesic | |
| CN117224733A (en) | Medical recombinant III type humanized collagen liquid | |
| CN115721674B (en) | Composition for wound care and application thereof | |
| CN117045844B (en) | Dressing containing polysaccharide and preparation method and application thereof | |
| CN115554465B (en) | Freeze-dried absorbable collagen-based medical dressing and preparation method thereof | |
| CN116983463A (en) | Hydrogel wound dressing and preparation method thereof | |
| CN108853369A (en) | The preparation method and application of natural plants antimicrobial fluid PAMs hydrogel patch | |
| CN119033994A (en) | Antibacterial double-layer hydrogel dressing of traditional Chinese medicine and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230307 |
|
| RJ01 | Rejection of invention patent application after publication |